On June 19th, Gelunhui reported that its wholly-owned subsidiary, Seacross Pharma (Europe) Ltd., recently received approval from the French National Agency for Medicines and Health Products Safety to market the company's zoledronic acid injection. Zoledronic acid injection is mainly used to treat osteoporosis in postmenopausal women and adult men, osteoporosis induced by long-term glucocorticoid therapy in postmenopausal women and adult men, and adult Paget's disease of bone (osteitis deformans).
汇宇制药(688553.SH)：唑来膦酸注射液获得法国上市许可
Huayu Pharmaceuticals (688553.SH): Zoledronic acid injection has obtained French trading license.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.